{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000007","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.782322+00:00","generated_at":"2026-06-04T11:56:41.994754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Barinthus Bio FY2023 net loss $73.3M, revenue drops to $0.8M, cash down to $142.1M","bullets":["Net loss of $73.3M ($1.91 per share) vs net income of $5.3M in 2022; revenue fell to $0.8M from $44.7M on lower Vaxzevria royalties.","Cash and equivalents $142.1M at Dec 31, 2023, down from $194.4M; operating cash burn $50.9M.","R&D expenses rose to $44.9M (+$2.5M); G&A surged to $39.8M (+$33.4M) primarily due to a $7.6M foreign exchange loss.","Pipeline: positive HBV VTP-300 Phase 2 data; HPV VTP-200 APOLLO trial final results expected Q2 2024; celiac VTP-1000 Phase 1 initiation planned Q2 2024.","Secured up to $35M from CEPI for MERS candidate VTP-500; renamed from Vaccitech to Barinthus in Nov 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000007","json":"https://secwatch.observer/filing/0001828185-24-000007.json","markdown":"https://secwatch.observer/filing/0001828185-24-000007.md","text":"https://secwatch.observer/filing/0001828185-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/0001828185-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/brns-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:56:41.994754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c23562c054ec52ea452584ad2e3619973ecd9e7","claim":"Barinthus Biotherapeutics plc. reported the year ended December 31, 2023 results: revenue $0.8 million, net income net loss of $73.4 million.","evidence_excerpt":"• Cash position: As of December 31, 2023, cash was $142.1 million, compared to $194.4 million as of December 31, 2022. The cash used in operating activities was $50.9 million, primarily resulting from our net loss of $73.4 million, adjusted by foreign exchange loss on translation of $7.5 million, share-based compensation of $5.1 million, depreciation and amortization of $5.4 million, deferred tax movements of $3.1 million and changes in our operating assets and liabilities, net of $6.2 million primarily related to a $5.8 million decrease in accounts receivable, a $2.2 million decrease in prepaid expenses and other current assets, $3.4 million decrease in accounts payable and $2.0 million increase in accrued expenses. • Revenue: Revenue was $0.8 million in 2023 compared to $44.7 million in 2022 and was comprised of the Company’s share of royalties received by Oxford University Innovation as a result of commercial sales of Vaxzevria® by AstraZeneca, sales of which reduced significantly i","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000007/0001828185-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$0.8 million"},{"label":"Net income","value":"net loss of $73.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}